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ABSTRACT
Background: Glioblastoma is the most malignant tumor of the central nervous 
system and still lacks effective treatment. This study explores mutational biomarkers 
of 11 drugs targeting either the RTK/Ras/PI3K, the p53 or the Rb pathway using 25 
patient-derived glioblastoma stem-like cell cultures (GSCs).
Results: We found that TP53 mutated GSCs were approximately 3.5 fold more 
sensitive to dual inhibition of mammalian target of rapamycin complex 1 and 2 
(mTORC1/2) compared to wild type GSCs. We identified that Bcl-2(Thr56/Ser70) 
phosphorylation contributed to the resistance of TP53 wild type GSCs against dual 
mTORC1/2 inhibition. The Bcl-2 inhibitor ABT-263 (navitoclax) increased sensitivity 
to the mTORC1/2 inhibitor AZD8055 in TP53 wild type GSCs, while sensitivity to 
AZD8055 in TP53 mutated GSCs remained unchanged.
Conclusion: Our data suggest that Bcl-2 confers resistance to mTORC1/2 
inhibitors in TP53 wild type GSCs and that combined inhibition of both mTORC1/2 
and Bcl-2 is worthwhile to explore further in TP53 wild type glioblastomas, whereas 
in TP53 mutated glioblastomas dual mTORC1/2 inhibitors should be explored.
INTRODUCTION
Glioblastoma is the most frequently occurring 
primary malignant tumor of the central nervous system 
[1]. Since the introduction of temozolomide in 2005 [2], 
clinical studies testing novel agents for glioblastoma have 
failed to yield new therapeutic options [3, 4]. Given the 
heterogeneous mechanisms by which these drugs exert 
their anti-tumor activity, it is likely that only a subset of 
patients harboring specific molecular aberrations in their 
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tumors would benefit from these agents. Therefore, it is 
imperative to preclinically identify predictive biomarkers 
that can be used to enrich clinical trials with patients who 
are likely to respond [5].
Recent studies have shown that glioblastomas 
contain aberrations largely in genes involved in 
Rb, p53 and receptor tyrosine kinase (RTK)/Ras/
phosphatidylinositol-3-kinase (PI3K) signaling pathways 
[6, 7]. In order to discover therapeutic biomarkers that 
might aid in identifying glioblastoma patients most likely 
to respond to drugs targeting these pathways, we tested 
a panel of 11 different small molecule compounds on 
25 patient-derived glioblastoma stem-like cell cultures 
(GSCs). GSCs are known to better preserve the gene 
expression profile [8], CNVs [8-10] and point mutations 
[9] of the parental tumor tissue than established cell lines. 
Furthermore, GSCs are more suitable for high-throughput 
drug screening compared to neurosphere cultures.
Herein, we present targeted exome sequencing of 
these 25 glioblastomas and drug sensitivity data of the 
corresponding patient-derived GSCs.
RESULTS
Exome sequencing data of parental glioblastoma 
tissue
To identify mutations present within our cohort of 
glioblastoma samples (N=25), we performed targeted 
exome sequencing of 1971 manually curated cancer-
related genes. 16 patient samples were derived from 
primary glioblastomas, and the remaining 9 from relapsed 
glioblastomas. In total, 829 mutations were detected, 
ranging from 9-68 (average=21.5, SD=13.3) and 11-
179 (average=53.9, SD=56.6) mutations in primary 
and relapsed glioblastomas, respectively. We identified 
36 recurrently mutated genes (occurring three or more 
times) and 9 recurrent copy number variations (CNV) 
(Supplementary Table S1). TTN, PTEN, EGFR and 
TP53 were amongst the top 4 most frequently mutated 
genes (Supplementary Table S1). PTEN, EGFR and 
TP53 mutations have previously been implicated in 
gliomagenesis [7], whereas TTN most likely is a passenger 
mutation [11].
Glioblastoma stem-like cell cultures respond 
heterogeneously to single compound treatments
To address the functional relevance of the 3 main 
deregulated pathways (RTK/Ras/PI3K, p53, Rb) in 
glioblastoma, we assembled a panel of 11 small molecule 
compounds either inhibiting the RTK/Ras/PI3K and Rb 
pathway, or reactivating the p53 pathway (Supplementary 
Table S2). We determined the GI50 (50% growth 
inhibitory concentration) after 8 days of drug exposure 
across 25 patient-derived GSCs. GSK2636771, a PI3Kß-
selective inhibitor, had a GI50 of >50 μM in several GSCs 
(data not shown), and was therefore excluded from further 
experiments due to its failure to inhibit cell proliferation 
potently.
We observed heterogeneous drug responses across 
the GSCs for 9 out of the remaining 10 compounds 
(GI50
SD
 >0.29 μM); only SNS-032 (CDK2/7/9 inhibitor) 
(GI50average =0.14 μM, GI50SD =0.056 μM) elicited a 
relatively homogeneous response across the 25 GSCs 
(Figure 1A). Unsupervised hierarchical clustering of 
Z-transformed drug sensitivity data did not reveal an 
obvious clustering pattern of the pathway-classified 
compounds (Supplementary Figure S1). Supervised 
clustering according to the pathway-classified compounds 
revealed a group of GSCs (4/25) which were on average 
at least 1.7 fold more resistant to 4 out of 5 RTK/Ras/PI3K 
targeting drugs and at least 1.5 fold more resistant to all 
(3/3) of the Rb pathway targeting compounds (Figure 1B). 
In contrast, this group was 5.7 fold more sensitive to the 
MDM2 inhibitor, Nutlin-3. There were no differences in 
drug sensitivity between primary and relapsed samples.
TP53 mutated GSCs are uniformly sensitive to 
dual mTORC1/2 inhibition but not uniformly 
sensitive to mTORC1 inhibition
In order to identify mutational biomarkers for the 
compounds used in this screen, we integrated the targeted 
exome sequencing data with the drug sensitivity data. 
To this end, we compared the GI50 values between the 
mutated and wild type samples for every gene containing 
a genetic aberration. We identified point mutations 
that were significantly correlated with GI50 values 
(unadjusted p<0.05, Wilcoxon rank-sum test) for 8 out of 
10 compounds (Table 1). However, we identified CNVs 
(PRKY and TBL1Y amplifications) that were significantly 
correlated with GI50 values (unadjusted p<0.05, Wilcoxon 
rank-sum test) for only one compound (PRIMA-1MET) 
(Supplementary Table S3).
We found that TP53 and TRRAP mutations were 
significantly associated with dual mTORC1/2 inhibition 
(FDR=0.026 and FDR=0.031, respectively, Wilcoxon rank-
sum test) (Supplementary Figure S2). Sanger sequencing 
was used to validate the presence of the TP53 mutations 
in the accompanying GSCs. Of the 6 TP53 mutations 
identified by next-generation sequencing, all mutations 
were validated (6/6). GSCs with a TP53 mutation (TP53mut) 
were more sensitive to the dual mTORC1/2 inhibitor 
AZD2014 than TP53 wild type (TP53wt) GSCs (GI50average 
=0.13 vs 0.45 μM, p=0.010, Wilcoxon rank-sum test). 
In contrast to the homogeneous response of the TP53mut 
cultures (GI50
SD
=0.041 μM), TP53wt cultures showed a more 
heterogeneous response (GI50
SD
=0.29 μM) (Figure 2A).
Next, we tested whether TP53mut GSCs are also 
sensitive to the AZD2014 drug analogue, AZD8055. GI50 
values of AZD2014 and AZD8055 were determined for 
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10 randomly selected GSCs after 5 days of drug exposure, 
and the results were highly correlated (ρ=0.93, spearman 
correlation) (Figure 2E). Similar to AZD2014 (GI50average 
=0.22 versus 0.81 μM, p=0.010, Wilcoxon rank-sum test), 
TP53mut GSCs were more sensitive to AZD8055 than 
TP53wt GSCs (GI50average =0.046 versus 0.18 μM, p=0.019, 
Wilcoxon rank-sum test) (Figure 2B). Live-cell imaging in 
response to 0.03 μM AZD8055 at t=200 hours confirmed 
that the TP53mut GSC was inhibited more than the TP53wt 
GSC (46% vs 7% inhibition) (Figure 2C, 2D).
To investigate whether TP53mut GSCs were 
uniformly sensitive to classic rapamycin analogues 
(mTORC1 inhibitors), we tested the previous set of 10 
GSCs for their response to sirolimus, temsirolimus and 
everolimus (Figure 2E). Although there was a moderate 
correlation between the GI50 values of mTORC1 
inhibitors and dual mTORC1/2 inhibitors (ρ = 0.41-0.72, 
spearman correlation) (Figure 2E), there was no significant 
difference between TP53mut and TP53wt type GSCs in 
response to mTORC1 inhibitors (sirolimus, p=0.32; 
temsirolimus, p=0.26; everolimus, p=0.67, Wilcoxon 
rank-sum test). While there was an initial response to 
the rapamycin analogues at low doses, a steady state was 
reached at approximately 50% cell viability (Figure 2F). 
For AZD2014 and AZD8055 however, a stronger initial 
response was observed, and the steady state was reached 
at around 25% cell viability (Figure 2F).
Phosphoproteome profiling identifies a Bcl-2 
inhibitor as a drug combination partner for 
AZD8055
The phosphoproteome is an important mediator 
of drug resistance. We investigated the phosphorylation 
pattern of 180 disease-relevant phosphosites using 
reverse phase protein arrays (RPPA) to identify possible 
therapeutic targets that might counter the resistance 
observed in TP53wt GSCs. A resistant TP53wt GSC 
(GS281) and 2 sensitive TP53mut GSCs (GS149 and 
GS186c) were exposed to 0.5 μM AZD8055 or 0.5 μM 
vehicle (DMSO) for 3 hours (Figure 3A). Ribosomal 
protein S6(Ser235-236) and Akt(Ser473) phosphorylation 
(used as a measure of mTORC1 and mTORC2 activity, 
respectively [12]) decreased in the AZD8055-treated 
GSCs compared to vehicle-treated GSCs (data not shown), 
strongly indicating the on-target inhibitory effect of 
AZD8055 on mTORC1 and mTORC2.
We compared the RPPA profiles of sensitive TP53mut 
GSCs (GS149 and GS186c) to the resistant TP53wt GSC 
(GS281). We identified phosphosites that were specifically 
hyperphosphorylated in the AZD8055-resistant GSC 
relative to both AZD8055-senstive GSCs (Figure 3B). 
NDRG1(Thr346), Akt (Ser473), AMPKb1(Ser108), 
4E-BP1(Thr70/Thr37.46), Bcl-2 (Thr56/Ser70), 
HSP27(Ser82), Cofilin(Ser3) were among the top 
Figure 1: GI50 values of 25 GSCs for a panel of small molecule compounds. A. Boxplot and dotplot in which each dot 
represents the GI50 value (μM) of a GSC to a specific compound. B. Supervised clustering of Z-transformed GI50 values (μM) was 
performed across the pathway-classified compounds. Unsupervised clustering was performed across the GSCs by complete linkage using 
euclidean distance. White, missing value; black rectangle, cluster of GSCs resistant to several compounds targeting the RTK/Ras/PI3K or 
Rb pathway.
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hyperphosphorylated phosphosites in the AZD8055-
resistant GSC relative to the AZD8055-sensitive GSCs.
Bcl-2 is a well known pro-survival protein broadly 
implicated in therapy resistance [13]. We combined the 
potent Bcl-2 inhibitor, ABT-263 [14], with AZD8055 to 
test for the reversal of resistance to AZD8055. Indeed, 
the addition of ABT-263 inhibited the proliferation of 
AZD8055-resistant GSC (GS281) more potently over a 
range of doses compared to AZD8055-sensitive GSCs 
(GS149 and GS186c) (Figure 3C).
DISCUSSION
Targeted therapy has not been proven effective yet 
for the treatment of glioblastoma [3, 4]. An underlying 
Table 1: Significant associations between mutated genes and drug response
Pathway Compound Target Mutation P (<0.05) FDR
RTK/Ras/PI3K Lapatinib EGFR, ERBB2 FBXW11 0.043 0.55
AZD2014 mTORC1,mTORC2 TP53 0.001 0.03
TRRAP 0.002 0.03
IGF2R 0.010 0.10
MLL5 0.011 0.10
FBXW11 0.036 0.26
GDC-0068 AKT1, AKT2, AKT3 TRRAP 0.006 0.22
IGF2R 0.020 0.36
BKM120 Class I PI3K isoforms FBXW11 0.006 0.11
(p110α, β, γ and δ) MLL5 0.008 0.11
TP53BP1 0.014 0.11
RNF213 0.015 0.11
SPEG 0.015 0.11
TP53 0.043 0.26
Crizotinib MET, ALK - - -
p53 Nutlin3 MDM2 MTOR 0.010 0.13
PIKFYVE 0.014 0.13
TYRO3 0.014 0.13
FBXW11 0.020 0.13
USP24 0.020 0.13
TP53 0.021 0.13
EGFR 0.041 0.21
PRIMA-1MET Mutant p53 RNF213 0.004 0.15
reactivation LAMA4 0.027 0.49
Alisertib AURKA - - -
Rb Palbociclib CDK4, CDK6 HDAC9 0.017 0.36
TRPM6 0.036 0.36
PIK3R1 0.040 0.36
SNS-032 CDK2, CDK7, CDK9 - - -
The compounds are grouped according to the pathway they interact with. The genes indicate that GSCs with and without 
the specific gene mutations vary significantly in GI50 value in response to the specific drug (unadjusted p<0.05, Wilcoxon 
rank-sum test). FDR, false discovery rate.
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reason for this failure may be due to the large intertumor 
heterogeneity of glioblastomas, as observed in sequencing 
studies [6, 7], rendering only a subset of tumors sensitive 
to a particular drug. It is therefore necessary to stratify 
patients or treatments guided by relevant predictive 
biomarkers [5]. Additionally, intratumor heterogeneity 
likely plays a major role in resistance to therapy [15]. 
Recent reports indicate that mutations can occur 
heterogeneously within a single glioblastoma [16, 17], 
and different tumor subclones can exhibit varying drug 
sensitivities [18, 19].
In this study, we focused on intertumor heterogeneity 
by identifying biomarkers of response using a panel of 25 
GSCs derived from different patients. GSCs are known 
Figure 2: TP53mut GSCs are uniformly sensitive to dual mTORC1/2 inhibition and not to mTORC1 inhibition. A, B. 
Boxplot and dotplot in which each dot, stratified by their TP53 mutation status, represents the GI50 values (μM) of AZD2014 or AZD8055 
(dual mTORC1/2 inhibitors) for GSCs. C, D. Live-image monitoring of proliferation in response to increasing concentrations of AZD8055. 
E. Spearman correlation of the GI50 values (μM) of different mTORC1 and dual mTORC1/2 inhibitors for 10 GSCs. F. Dose-response 
curves of the same 10 GSCs. The colors indicate the TP53 mutation status. Pink, TP53mut; blue, TP53wt; MUT, mutated; WT, wild type.
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to better preserve the gene expression profile [8], CNVs 
[8-10] and point mutations [9] of the parental tumor tissue 
than established cell lines. Furthermore GSCs are more 
suitable for high-throughput drug screening compared to 
neurosphere cultures.
Targeted exome sequencing integrated with our 
compound screen identified that TP53mut GSCs were 
uniformly sensitive to dual mTORC1/2 inhibition, but 
not mTORC1 inhibition alone; TP53wt GSCs were more 
heterogeneous in response to dual mTORC1/2 inhibition.
To the best of our knowledge, this is the first report 
identifying TP53 mutations as a biomarker for response 
to dual mTORC1/2 inhibition in glioblastoma. In other 
cancers, mTORC1 inhibition by rapamycin has previously 
been linked to selectively induce apoptosis in TP53mut 
rhabdomyosarcoma cell cultures [20, 21]. After rapamycin 
exposure, wild type p53 induces p21cip expression, which 
leads to a G1 phase cell cycle arrest [20, 22]. In contrast, 
TP53mut or deficient cells undergo cell cycle progression 
and subsequent apoptosis [20, 22]. In this study however, 
we could not find any significant difference in sensitivity 
to mTORC1 inhibition between TP53mut and TP53wt GSCs. 
mTORC2 is increasingly recognized as an important 
mediator of gliomagenesis [23] and chemoresistance [24]. 
Future work is required to investigate whether TP53mut 
cells cannot survive without mTORC2 activity, and 
whether mTORC2 specific inhibition would selectively 
kill TP53mut cells. The future development of mTORC2 
specific inhibitors is important, since they may have a 
large therapeutic window as mTORC2 appears to be 
redundant in normal tissue [25].
We sought to understand the difference in response 
between TP53mut AZD8055-sensitive and TP53wt 
AZD8055-resistant GSCs. Through comparison of their 
Figure 3: Kinome profiling identifies potential phosphosites implicated in resistance to AZD8055. A. Schematic depiction 
of the approach for dynamic kinome profiling. B. Waterfall plot of the 180 phosphosites. The values above and below 0 indicate respectively 
hyper- and hypophosphorylated phosphosites in the resistant TP53wt (red) GSC relative to the sensitive TP53mut (green) GSCs after exposure 
to AZD8055. C. Increasing doses of ABT-263 and AZD8055 were tested in the AZD8055-resistant TP53wt GSC (GS281) and two AZD8055-
sensitive TP53mut GSCs (GS149 and GS186c).
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RPPA profiles, we identified Bcl-2 as being implicated in 
resistance to AZD8055. These findings were supported 
by the observation that the TP53wt AZD8055-resistant 
GSC was more sensitive to combined exposure of 
AZD8055 and ABT-263 than TP53mut GSCs. Although 
this combination therapy was effective in TP53wt GSCs, it 
is still unclear whether this is also the case in vivo. There 
are multiple studies showing that mTORC1/2 inhibitors 
can cross the blood-brain barrier (BBB) and interfere 
with glioblastoma growth in preclinical orthotopic in 
vivo models [26, 27], whereas it is still unknown whether 
ABT-263 can efficiently penetrate the BBB. Interestingly, 
in concordance with our findings, another study also found 
this combination to be synergistic in a subset of GSCs 
[28]. Collectively, our findings suggest that RPPA can be 
systematically used to identify phosphoproteins involved 
in resistance to therapy.
The clinical relevance of dual mTORC1/2 inhibition 
by AZD8055 or AZD2014 is yet to be fully elucidated. 
In a recent study, AZD8055 was shown to synergize with 
temozolomide, leading to a 30% prolonged survival of 
orthotopic glioma xenografts compared to treatment with 
either drug alone [26]. TP53 is mutated or deleted in 
around 30% of glioblastomas [7]; for these patients, TP53 
mutations may be used as a biomarker to stratify patients 
for dual mTORC1/2 inhibitor treatment, thus enhancing 
the effect of combination therapy employing AZD2014 or 
AZD8055 with temozolomide.
In conclusion, our data suggest that TP53 mutations 
are a predictive biomarker of response to dual mTORC1/2 
inhibitors, rendering it worthwhile to further explore 
dual mTORC1/2 inhibitors in TP53mut glioblastomas. 
Furthermore, TP53wt GSCs are resistant against 
mTORC1/2 inhibitors via Bcl-2; combined blockade 
of mTORC1/2 and Bcl-2 is worth exploring further in 
TP53wt glioblastomas, or in TP53mut tumors to prevent 
the outgrowth of resistant subclones during mTORC1/2 
inhibition.
MATERIALS AND METHODS
Patient-derived glioblastoma cultures
Resected human glioblastoma tumor material 
was obtained at the departments of neurosurgery of the 
Erasmus Medical Center (Rotterdam, The Netherlands) 
and Elisabeth Hospital (Tilburg, The Netherlands). Tumor 
material, that was safely accessible, was resected and 
used for research with the patient’s written consent and in 
accordance with protocols approved by the institutional 
review board of the Erasmus Medical Center. A portion of 
the tumor tissue specimens was dissociated and maintained 
as adherent GSCs under serum-free culture conditions as 
was described previously [10]. The adjacent portion of the 
tumor tissue was snap-frozen and used for next-generation 
sequencing. 25 GSCs were used for the experiments.
Next generation sequencing
We performed targeted exome sequencing of 
a “cancer mini-genome” consisting of 1971 cancer-
related genes based on [29]. DNA was extracted using 
NorDiag Arrow (Isogen Life Science, De Meern, the 
Netherlands) and quantified with a Qubit 2.0 fluorometer 
(Life Technologies, Carlsbad, USA). Barcoded fragment 
libraries were generated from 600 ng of isolated DNA 
from tumor samples as previously described [30]. 
Pools of libraries were enriched for the cancer mini-
genome using SureSelect technology. The enriched 
libraries were sequenced on a SOLiD 5500xl (Applied 
Biosystems, Foster City, USA) instrument according to the 
manufacturers’ protocol. Afterwards, the sequenced data 
were mapped to the reference genome (GRCh37/hg19) 
using Burrows-Wheeler Aligner [31]. Variant calling was 
performed using a custom pipeline as previously described 
[32]. Copy number status of a selected set of genes from 
the targeted sequencing data was estimated using modified 
Z-scores as described previously [33]. Copy number data 
from GS186p, GS289 and GS454 were excluded due to 
suboptimal quality.
Small molecule compounds
The following small molecule compounds targeting 
the RTK/Ras/PI3K pathway were diluted in DMSO 
(Sigma-Aldrich, St. Louis, USA): lapatinib ditosylate 
was obtained from Santa Cruz Biotechnology (Dallas, 
USA) (catalog number 202205A). Crizotinib (S1068), 
NVP-BKM120 (S2247), GDC-0068 (S2808), AZD2014 
(S2783), AZD8055 (S1555) and GSK2636771 (S8002) 
were obtained from Selleck Chemicals (Houston, USA).
The following small molecule compounds targeting 
the Rb pathway were diluted in DMSO: SNS-032 (S1145) 
was obtained from Selleck Chemicals. Palbociclib 
isethionate (PD-0332991) (S1579) was diluted in milliQ 
water and was obtained from Selleck Chemicals.
The following small molecule compounds targeting 
the p53 pathway were diluted in DMSO: Nutlin3 (S1061) 
and Alisertib (MLN8237) (S1133) were obtained from 
Selleck Chemicals. PRIMA-1MET (SC-361295) was 
obtained from Santa Cruz Biotechnology.
The following small molecule compound was 
identified as a potential combination partner of AZD8055 
and was diluted in DMSO: ABT-263 (11500) was obtained 
from Cayman Chemical (Ann Arbor, USA).
Viability assay
All viability assays were performed with GSCs 
below passage 20 using the CellTiter-Glo assay (Promega, 
WI, USA). Dose–response assays were performed in three 
step dilutions at six different concentrations in order to 
determine the growth inhibitory concentration required 
to inhibit 50% of cell proliferation (GI50). The 96-well 
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plates were coated with matrigel (1:20, Trevigen, MD, 
USA) and seeded at 0.8-1.0x103 cells/well and were left 
to adhere for 24 hours. After 24 hours the compounds 
were added to the wells. Cell viability was measured on 
day five or eight after treatment by using the luminescent 
CellTiter-Glo assay (Promega, WI, USA) according 
to the manufacturer’s protocol. Luminescence was 
measured with a Tecan Infinite Reader (Tecan Group 
Ltd., Männedorf, Switzerland). The GI50 values were 
calculated by median effect equation [34].
Live-cell imaging
The cells were seeded at 1.0x104 cells/well in a 
matrigel coated (1:20) 24-well plate and were left to 
adhere for 24 hours. Hereafter DMSO (control) and 
AZD8055 were added at the indicated concentrations in 
duplicate. The 24-well plates were placed in an IncuCyte 
(Essen BioScience, MI, USA) at 37°C in a humid 95% 
air/5% CO2 chamber. Three phase contrast images/well 
were collected with a 10× objective every 4 hours for 
up to 9 days after addition of AZD8055. The percentage 
of the area of the well occupied by cells (confluence) 
was calculated using software of the IncuCyte live-cell 
imaging system (Essen BioScience).
Reverse phase protein array (RPPA)
One AZD8055-resistant TP53wt GSC (GS281) and 2 
AZD8055-sensitive TP53mut GSCs (GS149 and GS186c) 
were analyzed by RPPA. First, the GSCs were cultured 
until 80% confluence in matrigel coated (1:20, Trivigen) 
T175 flasks. Afterwards the cells were trypsinized and 
transferred to non-coated T175 flasks where they were 
cultured for 24 hours as neurospheres. Then, cells were 
exposed to 0.5 μM AZD8055 for 3 hours. Hereafter 
cell pellets were prepared following Carna Biosciences’ 
protocol and stored at -80°C. The cell pellet was thawed 
on ice and cell lysates were prepared in 50 μl lysis buffer 
following Carna Biosciences’ protocol. The protein 
concentrations were measured using the Bradford protein 
assay and were provided to Carna Biosciences together 
with the cell lysates. The lysates were further processed and 
analyzed by Carna Biosciences (Kobe, Japan) according 
to their protocol. In short, the lysates were spotted onto 
glass slides and immunostaining was performed with 
180 antibodies (one antibody per slide). The signals 
were then measured as fluorescence of the fluorophore-
labeled secondary antibodies and normalized with the 
values for gamma-tubulin (loading control). The raw 
data and calculated relative concentrations were reported 
back. For each GSC the AZD8055-treated condition was 
divided by the DMSO-treated values. As a result, the fold 
change between the AZD8055-treated and DMSO-treated 
conditions was derived for each phosphosite of the 3 
GSCs. The fold change of the AZD8055-resistant TP53wt 
GSC (GS281) were divided by the averaged fold change 
of the 2 AZD8055-sensitive TP53mut GSCs (GS149 and 
GS186c). This enabled the identification of phosphosites 
that were hyperphosphorylated in the AZD8055-resistant 
GSC (GS281) compared to the 2 AZD8055-sensitive 
GSCs (GS149 and GS186c).
Analysis of mutations in relation to drug 
sensitivity
The growth inhibitory concentration required to 
inhibit 50% of cell proliferation compared to non-treated 
control cells (GI50) was correlated to the presence or 
absence of mutated genes. Wilcoxon rank-sum tests were 
performed to statistically compare the GI50 values of 
mutated and wild type cultures for each aberrant gene 
(mutated, amplified or deleted) recurring three or more 
times among the patient-derived glioblastoma cultures. 
The false discovery rate was used to correct for multiple 
testing.
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